

=> d his

(FILE 'HOME' ENTERED AT 16:33:18 ON 05 JAN 2007)

FILE 'USPATFULL, CAPLUS' ENTERED AT 16:33:45 ON 05 JAN 2007

L1	7 FILE USPATFULL
L2	752 FILE CAPLUS
TOTAL FOR ALL FILES	
L3	759 S (FIBRINOGEN (1S) LIPID?)/AB
L4	5 FILE USPATFULL
L5	58 FILE CAPLUS
TOTAL FOR ALL FILES	
L6	63 S L2 AND COMPOSITION
L7	2 FILE USPATFULL
L8	0 FILE CAPLUS
TOTAL FOR ALL FILES	
L9	2 S FIBRIN GEL AND L6
L10	3 FILE USPATFULL
L11	1 FILE CAPLUS
TOTAL FOR ALL FILES	
L12	4 S FIBRIN AND GLUE AND L6
L13	1 FILE USPATFULL
L14	1 FILE CAPLUS
TOTAL FOR ALL FILES	
L15	2 S L12 NOT L9
L16	45 FILE USPATFULL
L17	0 FILE CAPLUS
TOTAL FOR ALL FILES	
L18	45 S (FIBRINOGEN (1S) LIPID?)/CLM

=> save all temp

ENTER NAME OR (END):l10664561/1

L# LIST L1-L18 HAS BEEN SAVED AS 'L10664561/L'

=>

L3 ANSWER 6 OF 759 USPATFULL on STN

AB High purity antithrombin III is recovered from a procedure in which the other protein fractions in human blood plasma are recovered for further processing. The protein fractions are recovered sequentially in separate steps: **fibrinogen** and Factor VIII are recovered as a precipitate; prothrombin complex is recovered on the surface of finely divided tricalcium phosphate; albumin and gamma globulin are recovered in an aqueous supernate; a protein precipitate containing **lipids**, lipoproteins and other trace protein contaminants is recovered; and antithrombin III is recovered as a precipitated phase. The **fibrinogen**, Factor VIII, prothrombin complex, albumin, gamma globulin and protein contaminants are all recovered in such a way that they are suitable for further processing.

ACCESSION NUMBER: 78:22825 USPATFULL

TITLE: Antithrombin III

INVENTOR(S): Bick, Rodger L., Los Angeles, CA, United States

Fekete, Lajos F., Costa Mesa, CA, United States

PATENT ASSIGNEE(S): Wilson, William L., Santa Monica, CA, United States
(U.S. individual)

Bick, Rodger L., Santa Monica, CA, United States (U.S.
individual)

Fekete, Lajos F., Santa Monica, CA, United States (U.S.
individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4087415		19780502
APPLICATION INFO.:	US 1976-694167		19760609 (5)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Danison, Walter C.		
LEGAL REPRESENTATIVE:	Hubbell, Cohen, Stiefel & Gross		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		

L6 ANSWER 63 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

TI The lipide content and the electrophoretic determination of the protein **composition** of serum and the fibrinogen content of the plasma in leprosy

AB . . . albumin 54.5-60.2, 35.1-49.1; α -globulin 5.1-7.5, 5.4-13.3; β -globulin 12.5-15.8, 11.1-13.3; γ -globulin 20.6-24.8, 28.7-45.4; and total globulin 39.8-45.5, 50.9-64.9%, resp. The serum **lipide** concns. were as follows: total fatty acids 469-701 in I, 618-1111 mg. % in II; total cholesterol 120-195, 137-195 mg.. . . 48-70% of the total cholesterol; phosphatide 57-157, 41-210 mg. %; and neutral fatty acids 341-638, 484-926 mg. %, resp. The **fibrinogen** content of the plasma was 0.51-0.96% in I and 0.43-0.58 in II. The thymol turbidity reaction was increased and the. . .

ACCESSION NUMBER: 1953:7040 CAPLUS

DOCUMENT NUMBER: 47:7040

ORIGINAL REFERENCE NO.: 47:1273f-h

TITLE: The lipide content and the electrophoretic determination of the protein **composition** of serum and the fibrinogen content of the plasma in leprosy

AUTHOR(S): Patiala, Risto; Raekallio, Tapio

CORPORATE SOURCE: Univ. Helsinki, Finland

SOURCE: Ann. Med. Exptl. et Biol. Fenniae (1951), 29, 335-9

DOCUMENT TYPE: Journal

LANGUAGE: German

=>

L6 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AB The following mean values (mg%) were found in Jaffarabadi buffalo cows:
fibrinogen 1206, total lipids 816, cholesterol 115, and
urea 24.4.
ST blood buffalo normal compn; lipid cholesterol blood buffalo;
fibrinogen blood buffalo
IT Buffalo
(blood compn. of)
IT Blood
(of buffalo, compn. of)
ACCESSION NUMBER: 1974:423627 CAPLUS
DOCUMENT NUMBER: 81:23627
TITLE: Total lipids, cholesterol, urea, and fibrinogen in the
blood of buffalo
AUTHOR(S): Antunes de Alencar Filho, Rufino
CORPORATE SOURCE: Sec. Patrol. Clin., Inst. Biol., Sao Paulo, Brazil
SOURCE: Biologico (1973), 39(9), 223-4
CODEN: BIOGAL; ISSN: 0366-0567
DOCUMENT TYPE: Journal
LANGUAGE: Portuguese

L6 ANSWER 45 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Pharmaceutical **composition** for preventing pathological processes
 AB . . . by i.v. injection of 15 mg rat fibrinogen. Labeled fibrinogen
 injected i.v. was transported to the site of inflammation. Human
fibrinogen was inactive in rats. The antiinflammatory agent
 phenylbutazone (I) [50-33-9], injected s.c. (200 mg/kg) into rats with
 inflammation induced by carrageenan or **lipid A**, enhanced the
 elevation of certain plasma proteins above that seen in rats with
 inflammation which did not receive I, . . .

ACCESSION NUMBER: 1979:61229 CAPLUS
 DOCUMENT NUMBER: 90:61229
 TITLE: Pharmaceutical **composition** for preventing
 pathological processes
 INVENTOR(S): Ruhenstroth-Bauer, Gerhard; Scherer, Reiner
 PATENT ASSIGNEE(S): Max-Planck-Gesellschaft zur Foerderung der
 Wissenschaften e.V., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 27 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2722769	A1	19781123	DE 1977-2722769	19770520
DE 2722769	B2	19801009		
DE 2722769	C3	19810806		
GB 1603244	A	19811118	GB 1978-18751	19780510
US 4215109	A	19800729	US 1978-906442	19780517
CH 644762	A5	19840831	CH 1978-5384	19780518
JP 54017107	A	19790208	JP 1978-59873	19780519
JP 63041890	B	19880819		
PRIORITY APPLN. INFO.:			DE 1977-2722769	A 19770520
			DE 1977-2750920	A 19771115

S PATENT.

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AB . . . for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting compn. The compn. may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, anti-inflammatory compds., antimicrobial compns., cytokines, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Heparin binding growth factor-1 (HBGF-1) was added at 10 µg in a fibrinogen complex containing heparin 10, thrombin 0.5 U/mL, and CaCl2 40 mM for testing the HBGF-1 diffusion from a fibrin glue clot.

ST fibrin tissue sealant supplement

IT Antibodies

Bone morphogenetic proteins

Cytokines

DNA

Fibrinogens

Fibrins

Fibronectins

Growth factors, animal

Hormones, animal, biological studies

Interferons

Lipids, biological studies

Mineral elements, biological studies

Oligonucleotides

Peptides, biological studies

Platelet-derived growth factors

Polynucleotides

Polysaccharides, biological studies

Proteins, general, biological studies

Proteoglycans, biological studies

RNA

Steroids, biological studies

Transforming growth factors

Vitamins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(supplemented and unsupplemented tissue sealants)

ACCESSION NUMBER: 2000:636163 CAPLUS

DOCUMENT NUMBER: 133:227868

TITLE: Supplemented and unsupplemented tissue sealants,
method of their production and use

INVENTOR(S): MacPhee, Martin James; Drohan, William Nash; Liao,
Gene; Haudenschild, Christian

PATENT ASSIGNEE(S): The American National Red Cross, USA

SOURCE: U.S., 79 pp., Cont.-in-part of U.S. Ser. No. 351,006,
abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6117425	A	20000912	US 1995-474086	19950607
EP 1142581	A2	20011010	EP 2001-113651	19911127
EP 1142581	A3	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AU 9884192	A	19981105	AU 1998-84192	19980911

AU 733471
US 39192
JP 2006297130
PRIORITY APPLN. INFO.:

B2 20010517
E1 20060718
A 20061102

US 2003-465854 20030620
JP 2006-178637 20060628
US 1990-618419 B2 19901127
US 1991-798919 B2 19911127
US 1993-31164 B1 19930312
US 1994-328552 B2 19941025
US 1994-351006 B2 19941207
EP 1992-901268 A3 19911127
AU 1994-63648 A3 19940314
JP 1994-520353 A3 19940314
US 1995-474086 A 19950607

REFERENCE COUNT:

61

THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 39 OF 45 USPATFULL on STN

CLM What is claimed is:

1. A liposome wherein a hemostatically effective amount of a C.sub.8
-C.sub.20 acylated fibrinogen is covalently incorporated into
the lipid bilayer of said liposome.

ACCESSION NUMBER: 97:73304 USPATFULL
TITLE: Fibrinogen-coated liposomes
INVENTOR(S): Retzinger, Gregory Scott, Cincinnati, OH, United States
Deanglis, Ashley P., Cincinnati, OH, United States
PATENT ASSIGNEE(S): University of Cincinnati, Cincinnati, OH, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5658588		19970819
APPLICATION INFO.:	US 1995-414368		19950331 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kishore, Gollamudi S.		
LEGAL REPRESENTATIVE:	Frost & Jacobs		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
LINE COUNT:	760		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 36 OF 45 USPATFULL on STN

CLM What is claimed is:

. . . an antiangiogenin, an antifibrinolytic compound, an antimicrobial compound, an antiparasitic agent, an antiseptic, an antiviral compound, a chemotherapeutic drug, a lipid or liposome, an oligonucleotide or polynucleotide, an osteoconductive compound, a polysaccharide, a vasoconstrictor, a vasodilator, a vitamin, a nutritional supplement and a mineral; and (ii) fibrinogen in an amount which forms a fibrin matrix; wherein said fibrinogen forms a fibrin matrix when in the presence of. . .

ACCESSION NUMBER: 2000:121069 USPATFULL

TITLE: Supplemented and unsupplemented tissue sealants, method of their production and use

INVENTOR(S): MacPhee, Martin James, Gaithersburg, MD, United States
Drohan, William Nash, Springfield, VA, United States
Liau, Gene, Darnestown, MD, United States
Haudenschild, Christian, Rockville, MD, United States
PATENT ASSIGNEE(S): The American National Red Cross, Falls Church, VA,
United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 6117425	20000912
---------------------	------------	----------

APPLICATION INFO.:	US 1995-474086	19950607 (8)
--------------------	----------------	--------------

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-351006, filed on 7 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-328552, filed on 25 Oct 1994, now abandoned which is a continuation of Ser. No. US 1993-31164, filed on 12 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1990-618419, filed on 27 Nov 1990, now abandoned which is a continuation-in-part of Ser. No. US 1991-798919, filed on 27 Nov 1991, now abandoned	
-----------------------	--	--

DOCUMENT TYPE:	Utility
----------------	---------

FILE SEGMENT:	Granted
---------------	---------

PRIMARY EXAMINER:	Woodward, M Patrick
-------------------	---------------------

ASSISTANT EXAMINER:	Zeman, Mary K
---------------------	---------------

LEGAL REPRESENTATIVE:	Sterne, Kessler Goldstein & Fox P.L.L.C.
-----------------------	--

NUMBER OF CLAIMS:	57
-------------------	----

EXEMPLARY CLAIM:	1,2,3
------------------	-------

NUMBER OF DRAWINGS:	53 Drawing Figure(s); 36 Drawing Page(s)
---------------------	--

LINE COUNT:	4910
-------------	------

L18 ANSWER 35 OF 45 USPATFULL on STN

CLM What is claimed is:

... decreasing blood loss by intravenous injection, said method comprising administering to a subject a particle comprising a biocompatible matrix with **fibrinogen** within or on the surface of said particle, said biocompatible matrix selected from the group consisting of proteins, **lipids**, nucleic acids, and carbohydrates.

... due to the action of thrombin, said method comprising administering to a subject a particle comprising a biocompatible matrix with **fibrinogen** within or on the surface of said particle, said biocompatible matrix selected from the group consisting of proteins, **lipids**, nucleic acids, and carbohydrates.

ACCESSION NUMBER: 2002:258479 USPATFULL
TITLE: Protein particles for therapeutic and diagnostic use
INVENTOR(S): Yen, Richard C.K., Yorba Linda, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142046	A1	20021003
APPLICATION INFO.:	US 2002-42834	A1	20020108 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-952765, filed on 10 Apr 1998, GRANTED, Pat. No. US 6391343 A 371 of International Ser. No. WO 1996-US9458, filed on 4 Jun 1996, UNKNOWN A 371 of International Ser. No. US 1995-471650, filed on 6 Jun 1995, GRANTED, Pat. No. US 5725804 A 371 of International Ser. No. US 1995-554919, filed on 9 Nov 1995, PENDING A 371 of International Ser. No. US 1995-471650, filed on 6 Jun 1995, GRANTED, Pat. No. US 5725804 Continuation-in-part of Ser. No. US 1994-212546, filed on 14 Mar 1994, GRANTED, Pat. No. US 5616311 Continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-959560, filed on 13 Oct 1992, GRANTED, Pat. No. US 5308620 Continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	63		
EXEMPLARY CLAIM:	1		

L18 ANSWER 34 OF 45 USPATFULL on STN

CLM What is claimed is:

. . . means for stabilizing an agent, which is for measuring a extrinsic coagulation factor for blood coagulation function, comprising at least **fibrinogen**, Factor V, and thromboplastin or **lipidated** tissue factor, characterized by inhibiting biological function for Factor XIII.

6. An agent, which is for measuring a extrinsic coagulation factor for blood coagulation function, comprising at least **fibrinogen**, Factor V, and thromboplastin or **lipidated** tissue factor, characterized by inhibiting biological function for Factor XIII, or characterized by being stabilized by adding effective amount of. . .

ACCESSION NUMBER: 2003:64751 USPATFULL

TITLE: Means of stabilizing compositions and reagents

INVENTOR(S): Okuda, Masahiro, Kobe-shi, JAPAN

Hiura, Hisahide, Kobe-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003044872	A1	20030306
APPLICATION INFO.:	US 2002-168756	A1	20020618 (10)
	WO 2000-JP9131		20001222

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-366663	19991224
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Luke A Kilyk, Kilvk & Bowersox, 53 A East Lee Street, Warrenton, VA, 20186	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	400	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 33 OF 45 USPATFULL on STN

CLM What is claimed is:

. . . an antiviral compound, a cytokine, a cytotoxin or cell proliferation inhibiting compound, a chemotherapeutic drug, a hormone, an interferon, a lipid, an oligonucleotide, a polysaccharide, a protease inhibitor, a proteoglycan, a polypeptide, a steroid, a vasoconstrictor, a vasodilator, a vitamin, and a mineral, and (ii) **fibrinogen**, or a derivative or metabolite thereof, in an amount which forms a fibrin matrix; and (b) applying said supplemented tissue. . .

ACCESSION NUMBER: 2003:123327 USPATFULL

TITLE: Method of preparing a tissue sealant-treated biomedical material

INVENTOR(S): Burgess, Willson H., Gaithersburg, MD, United States
Greisler, Howard P., Chicago, IL, United States
Drohan, William N., Springfield, VA, United States
Maciag, Thomas, Rockville, MD, United States
MacPhee, Martin J., Gaithersburg, MD, United States

PATENT ASSIGNEE(S): Loyola University of Chicago, United States (U.S. corporation)
The American National Red Cross, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6559119	B1	20030506

APPLICATION INFO.: US 1995-486048 19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-351006, filed on 7 Dec 1994, now abandoned Continuation-in-part of Ser. No. US 1994-328552, filed on 25 Oct 1994, now abandoned Continuation of Ser. No. US 1993-31164, filed on 12 Mar 1993, now abandoned Continuation-in-part of Ser. No. US 1990-618419, filed on 27 Nov 1990, now abandoned Continuation-in-part of Ser. No. US 1991-798919, filed on 27 Nov 1991, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Witz, Jean C.

LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox, P.L.L.C.

NUMBER OF CLAIMS: 36

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 50 Drawing Figure(s); 36 Drawing Page(s)

LINE COUNT: 4892

CAS INDEXING IS AVAILABLE FOR THIS PATENT.